X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Fox2 / RBM9 antibody

RRID:AB_2285090

Antibody ID

AB_2285090

Target Antigen

Fox2 / RBM9 antibody human, mouse

Proper Citation

(Abcam Cat# ab57154, RRID:AB_2285090)

Clonality

monoclonal antibody

Comments

validation status unknown, seller recommendations provided in 2012:2a;2a Western Blot; Immunohistochemistry; Immunohistochemistry - fixed; Flow Cytometry; Flow Cyt, ICC, IHC-FoFr, IHC-P, WB; Immunohistochemistry - frozen; Immunocytochemistry

Host Organism

mouse

Vendor

Abcam

Cat Num

ab57154

Publications that use this research resource

Protection against high-fat diet-induced obesity in Helz2-deficient male mice due to enhanced expression of hepatic leptin receptor.

  • Yoshino S
  • Endocrinology
  • 2014 Sep 25

Literature context:


Abstract:

Obesity arises from impaired energy balance, which is centrally coordinated by leptin through activation of the long form of leptin receptor (Leprb). Obesity causes central leptin resistance. However, whether enhanced peripheral leptin sensitivity could overcome central leptin resistance remains obscure. A peripheral metabolic organ targeted by leptin is the liver, with low Leprb expression. We here show that mice fed a high-fat diet (HFD) and obese patients with hepatosteatosis exhibit increased expression of hepatic helicase with zinc finger 2, a transcriptional coactivator (Helz2), which functions as a transcriptional coregulator of several nuclear receptors, including peroxisome proliferator-activated receptor γ in vitro. To explore the physiological importance of Helz2, we generated Helz2-deficient mice and analyzed their metabolic phenotypes. Helz2-deficient mice showing hyperleptinemia associated with central leptin resistance were protected against HFD-induced obesity and had significantly up-regulated hepatic Leprb expression. Helz2 deficiency and adenovirus-mediated liver-specific exogenous Leprb overexpression in wild-type mice significantly stimulated hepatic AMP-activated protein kinase on HFD, whereas Helz2-deficient db/db mice lacking functional Leprb did not. Fatty acid-β oxidation was increased in Helz2-deficeint hepatocytes, and Helz2-deficient mice revealed increased oxygen consumption and decreased respiratory quotient in calorimetry analyses. The enhanced hepatic AMP-activated protein kinase energy-sensing pathway in Helz2-deficient mice ameliorated hyperlipidemia, hepatosteatosis, and insulin resistance by reducing lipogenic gene expression and stimulating lipid-burning gene expression in the liver. These findings together demonstrate that Helz2 deficiency ameliorates HFD-induced metabolic abnormalities by stimulating endogenous hepatic Leprb expression, despite central leptin resistance. Hepatic HELZ2 might be a novel target molecule for the treatment of obesity with hepatosteatosis.

Funding information:
  • NIDDK NIH HHS - DK081546(United States)
  • NINDS NIH HHS - R37 NS037096(United States)